Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Chrysalis Pharma AG
DescriptionUltra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacromolecule: Fatty acid/lipid
Latest Stage of DevelopmentApproved
Standard IndicationHypertriglyceridemia
Indication DetailsTreat hypertriglyceridemia; Treat severe hypertriglyceridemia
Regulatory Designation U.S. - Special Protocol Assessment (Treat hypertriglyceridemia);
U.S. - Standard Review (Treat severe hypertriglyceridemia)
Partner AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today